I missed this one during #ACR19 (found via @RheumNow's weekly roundup):
Abstract L19: Early study, but BAFF inhibitor Ianalumab met its primary endpoint in primary Sjogren's.https://acrabstracts.org/abstract/ianalumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/ …
0 replies
10 proslijeđenih tweetova
27 korisnika označava da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
I've had today. Never skip leg day.